These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Trends in Mineral Metabolism Treatment Strategies in Patients Receiving Hemodialysis in the United States. Hall R; Platt A; Wilson J; Ephraim PL; Hwang AS; Chen A; Weiner DE; Boulware LE; Pendergast J; Scialla JJ; Clin J Am Soc Nephrol; 2020 Nov; 15(11):1603-1613. PubMed ID: 33046525 [TBL] [Abstract][Full Text] [Related]
3. Racial differences in clinical use of cinacalcet in a large population of hemodialysis patients. Newsome BB; Kilpatrick RD; Liu J; Zaun D; Solid CA; Nieman K; St Peter WL Am J Nephrol; 2013; 38(2):104-14. PubMed ID: 23899621 [TBL] [Abstract][Full Text] [Related]
4. Cinacalcet for secondary hyperparathyroidism in end-stage renal disease patients below age 5 years . Joseph C; Shah S; Geer J; Juarez-Calderon M; Srivaths PR; Swartz SJ Clin Nephrol; 2019 Dec; 92(6):279-286. PubMed ID: 31587754 [TBL] [Abstract][Full Text] [Related]
5. Prescription patterns and mineral metabolism abnormalities in the cinacalcet era: results from the MBD-5D study. Fukagawa M; Fukuma S; Onishi Y; Yamaguchi T; Hasegawa T; Akizawa T; Kurokawa K; Fukuhara S Clin J Am Soc Nephrol; 2012 Sep; 7(9):1473-80. PubMed ID: 22822017 [TBL] [Abstract][Full Text] [Related]
6. Calcimimetic Use in Dialysis-Dependent Medicare Fee-for-Service Beneficiaries and Implications for Bundled Payment. Gooding M; Desai P; Owens H; Petrilla AA; Kambhampati M; Levine Z; Young J; Fagan J; Rubin R Kidney360; 2020 Oct; 1(10):1091-1098. PubMed ID: 35368776 [TBL] [Abstract][Full Text] [Related]
7. Parathyroidectomy and Cinacalcet Use in Medicare-Insured Kidney Transplant Recipients. Wang AX; Liu S; Montez-Rath ME; Chertow GM; Lenihan CR Am J Kidney Dis; 2023 Mar; 81(3):270-280.e1. PubMed ID: 36162617 [TBL] [Abstract][Full Text] [Related]
8. Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism. Sprague SM; Wetmore JB; Gurevich K; Da Roza G; Buerkert J; Reiner M; Goodman W; Cooper K Clin J Am Soc Nephrol; 2015 Jun; 10(6):1021-30. PubMed ID: 25873267 [TBL] [Abstract][Full Text] [Related]
9. Minimal impact of calcimimetics on the management of hyperparathyroidism in chronic dialysis. Brunaud L; Ngueyon Sime W; Filipozzi P; Nomine-Criqui C; Aronova A; Zarnegar R; Kessler M; Frimat L; Ayav C Surgery; 2016 Jan; 159(1):183-91. PubMed ID: 26476826 [TBL] [Abstract][Full Text] [Related]
10. Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study. Tentori F; Wang M; Bieber BA; Karaboyas A; Li Y; Jacobson SH; Andreucci VE; Fukagawa M; Frimat L; Mendelssohn DC; Port FK; Pisoni RL; Robinson BM Clin J Am Soc Nephrol; 2015 Jan; 10(1):98-109. PubMed ID: 25516917 [TBL] [Abstract][Full Text] [Related]
11. Timing of parathyroidectomy for tertiary hyperparathyroidism with end-stage renal disease: A cost-effectiveness analysis. McManus C; Oh A; Lee JA; Hur C; Kuo JH Surgery; 2021 Jan; 169(1):94-101. PubMed ID: 32732069 [TBL] [Abstract][Full Text] [Related]
12. A Randomized Trial of Cinacalcet versus Vitamin D Analogs as Monotherapy in Secondary Hyperparathyroidism (PARADIGM). Wetmore JB; Gurevich K; Sprague S; Da Roza G; Buerkert J; Reiner M; Goodman W; Cooper K Clin J Am Soc Nephrol; 2015 Jun; 10(6):1031-40. PubMed ID: 25904755 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of Cinacalcet on secondary hyperparathyroidism in Chinese chronic kidney disease patients receiving hemodialysis. Mei C; Chen N; Ding X; Yu X; Wang L; Qian J; Wang M; Jiang G; Li X; Hou F; Zuo L; Wang N; Liu H Hemodial Int; 2016 Oct; 20(4):589-600. PubMed ID: 26940692 [TBL] [Abstract][Full Text] [Related]
15. The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial. Parfrey PS; Drüeke TB; Block GA; Correa-Rotter R; Floege J; Herzog CA; London GM; Mahaffey KW; Moe SM; Wheeler DC; Kubo Y; Dehmel B; Goodman WG; Chertow GM; Clin J Am Soc Nephrol; 2015 May; 10(5):791-9. PubMed ID: 25710802 [TBL] [Abstract][Full Text] [Related]
16. Calcimimetic use in US hemodialysis facilities in first 2 years after the launch of etelcalcetide: A descriptive analysis of real-world clinical practice and outcomes. Stephens JM; Fox KM; Desai P; Cheng S; Goodman WG; Kendrick JB Hemodial Int; 2022 Apr; 26(2):243-254. PubMed ID: 34931443 [TBL] [Abstract][Full Text] [Related]
17. Etelcalcetide Versus Cinacalcet in Hemodialysis Patients in the United States: A Facility Calcimimetic Approach to Assess Real-World Effectiveness. Karaboyas A; Muenz D; Hwang Y; Goodman W; Cheng S; Desai P; Fox KM; Robinson BM; Pisoni RL Kidney Med; 2022 Jun; 4(6):100475. PubMed ID: 35637925 [TBL] [Abstract][Full Text] [Related]
18. Mineral bone disorder and its management among hemodialysis patients in the Gulf Cooperation Council: Initial findings from the dialysis outcomes and practice patterns study (2012-2015). Al Salmi I; AlRukhaimi M; AlSahow A; Shaheen FA; Al-Ghamdi SM; AlAli F; AlGhareeb S; Al Maimani Y; AlGhonaim M; Bieber B; Tentori F; Pisoni RL; Saudi J Kidney Dis Transpl; 2016 Nov; 27(6 Suppl 1):62-80. PubMed ID: 27991480 [TBL] [Abstract][Full Text] [Related]
19. Cinacalcet use patterns and effect on laboratory values and other medications in a large dialysis organization, 2004 through 2006. St Peter WL; Li Q; Liu J; Persky M; Nieman K; Arko C; Block GA Clin J Am Soc Nephrol; 2009 Feb; 4(2):354-60. PubMed ID: 19129318 [TBL] [Abstract][Full Text] [Related]
20. Calcium-Sensing Receptor Genotype and Response to Cinacalcet in Patients Undergoing Hemodialysis. Moe SM; Wetherill L; Decker BS; Lai D; Abdalla S; Long J; Vatta M; Foroud TM; Chertow GM Clin J Am Soc Nephrol; 2017 Jul; 12(7):1128-1138. PubMed ID: 28630081 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]